A research study from the scientists at the National Institutes of Health and the University of Alabama, Birmingham (UAB) discovered that there was a connection between the genes that code for hair color and the genes that signal infection in the body. This study had revealed a reason as to why some people’s hair turn grey in response to an illness.
Global pharmaceutical company Mylan N.V. (MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.
A 10-month-old boy born without an immune system has been confined to his sanitized home his entire life and only leaves for doctor's visits. Sebastian Romero was diagnosed with severe combined immunodeficiency (SCID) at two weeks old, a rare genetic disorder known as 'bubble boy' disease that left him with no infection-fighting cells.
Monitoring disease activity in individuals with multiple sclerosis, either to predict flare-ups or to check treatment response, might be done with a simple blood test that measures levels of a nerve protein, according to a new study from Norway.
When bacteria enter our body, they kick-start a powerful immune response. But this chain of reactions doesn't fully account for our immediate responses. Researchers at KU Leuven, Belgium, show that so-called ion channels play a key role as 'first responders'.
Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response.
Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.